TG Therapeutics, Inc.
TGTX
NASDAQ·Healthcare·Biotechnology·Mkt cap $8.7B
$56.71
▼ -0.33%
P/E
20.51
Mkt Cap
$8.7B
52-Wk Range
$26.76–$59.30
52-Week Range
$26.76 - $59.30
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 79.4% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Glycoengineered monoclonal antibody technology with enhanced efficacy
- Dual-mechanism oral inhibitors targeting PI3K-delta and CK1-epsilon pathways
- Strategic partnerships with established pharmaceutical and biotech companies
- Selective BTK inhibitor candidate with improved safety profile versus competitors
Bear Case
2 risks
- Above-average volatility (beta 1.7).
- Growth premium of 2.5x vs Biotech & Therapeutics peers. Elevated but may be justified by growth trajectory.
Growth
Moderate growth ahead
Regulatory approvals and commercialization of Ublituximab and Umbralisib
Value
Growth premium of 2.5x vs Biotech & Therapeutics peers. Elevated but may be justified by growth trajectory.
Momentum
Hot
+41.9% over 3m
Quality
Excellent
High-growth business (76% revenue growth, 82% gross margin). Profitable with strong growth momentum.
Dividend
None
No dividend
Smart-money signal
Who's buying TGTX right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 2, 2026
AUG 3, 2026
Reported EPS of $0.05 vs $0.31 consensus (-83.6% surprise). Revenue of $240.3M vs $229.8M expected (+4.6%).
EPS surprise · last 4Q
0 of 1 beats
Estimate
Actual
Q3 26
-83.6%
Revenue trend · last 8Q
—
+146%
+90%
+92%
+93%
+78%
+70%
+70%
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$83.9M
$108.2M
$120.9M
$141.1M
$161.7M
$192.6M
$204.9M
$240.3M
Margins · last 8Q
Gross
82.9%
Operating
9.0%
Profit
3.2%
Wall Street consensus
2 analysts · 100% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
100%
Hold
0%
Sell
0%
Median Price Target
—
Latest: HC Wainwright · Aug 4, 2026
vs Industry
How TGTX stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related